NCT01521598View on ClinicalTrials.gov

A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study for the Pain of Diabetic Peripheral Neuropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Painful Diabetic Neuropathy
Interventions
DRUG

SKL11197

SKL11197 drug product contains 150 mg of active ingredient. Dosing will be three times per day.

DRUG

Placebo

This is the placebo. Patients will be randomized the placebo.

Trial Locations (13)

33471

Renstar Medical Research, Ocala

33603

Clinical Research of West Florida, Inc., Tampa

33716

Comprehensive Clinical Development, St. Petersburg

35476

Neurology Clinic, P.C., Northport

48104

Michigan Head Pain & Neurological Institute., Ann Arbor

66211

International Clinical Research Institute, Leawood

68131

Creighton Diabetes Center, Omaha

71901

Principals Research Group, Hot Springs

72205

Clinical Trials, Inc., Little Rock

77030

Nerve and Muscle Center of Texas, Houston

90404

Neurological Research Institute, Santa Monica

90806

Collaborative Neuroscience Network, Inc., Long Beach

97504

Sunstone Medical Research, LLC, Medford

All Listed Sponsors
lead

SK Life Science, Inc.

INDUSTRY

NCT01521598 - A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study for the Pain of Diabetic Peripheral Neuropathy | Biotech Hunter | Biotech Hunter